Eurand, a global specialty pharmaceutical company, today reported revenues for the fourth quarter of 2009 of €30.3 million ($43.4 million), a 28% increase in constant currency from the fourth quarter of 2008. For the year ended 31 December 2009, revenues grew to a record €120.6 million ($172.8 million), up 18% in constant currency from 2008.
Eurand, a global specialty pharmaceutical company, has announced the grant of U.S. Patent No. 7,658,918, titled Stable Digestive Enzyme Compositions, by the United States Patent and Trademark Office (USPTO).
Core laboratories RadPharm and Medifacts International recently merged business operations, hoping to attract new clients with their combined portfolios.
CoreLab Partners, Inc, the recently established global entity resulting from the merger between RadPharm and Medifacts International, has launched a new brand identity to reinforce their capabilities as one of the largest imaging sciences and cardiac safety core labs in the market today.
To coincide with the launch of the iPad™, DASGIP AG is expanding its Remote Control Suite for online bioreactor control with the introduction of its especially developed iPad application, now available on the App StoreSM.
IRW provides 24-7 medical support both during clinical development and after product authorisation.
IRW today announces the company's board of directors. IRW Board of Directors is responsible for the overall management of the organisation.
As part of our continuous effort to integrate a complete range of process development services for our customers, we have recently installed new equipment.
The German company NeuroProof GmbH has developed a database containing the electrophysiological action profiles of over 100 substances. The company uses primary neuronal cell cultures cultivated on microelectrode array neurochips which record and analyse the electrical pattern of the action potentials of individual nerve cells in complex networks. Data analysis is based on proprietary methods of pattern recognition and similarity analysis developed by the company.
Using a pioneering screening system, a team of Rostock‐based researchers has made an important contribution to the development of new pain relief drugs.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.